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Abstract  
Alzheimer’s disease, the commonest cause of dementia, is a growing global health 
concern with huge implications for individuals and society. In this review, we outline 
the current understanding of the epidemiology, genetics, pathology and 
pathogenesis of Alzheimer’s disease, before discussing its clinical presentation, and 
current treatment strategies. Finally, we discuss how our enhanced understanding of 
Alzheimer pathogenesis and the recognition of a protracted preclinical phase is 
informing new therapeutic strategies with the aim of moving from treatment to 
prevention. 
 
Introduction 
Alzheimer’s disease (AD) is recognised by the World Health Organisation as a global 
public health priority. Despite large gains in our understanding of AD pathogenesis 
and how we conceptualise the disease since Alois Alzheimer reported the first case 
in 1907 [1] there are still no disease-modifying treatments. Here we provide an 
overview of current thinking in AD, with respect to epidemiology, genetics, pathology 
and pathogenesis, before considering its clinical presentation, current treatment 
options and future therapeutic strategies. 
 
Epidemiology 
Dementia – acquired progressive cognitive impairment sufficient to impact on 
activities of daily living – is a major cause of dependence, disability and mortality. 
Current estimates suggest that 44 million people live with dementia worldwide 
presently. This is predicted to more than triple by 2050 as the population ages, when 
the annual cost of dementia in the US alone may exceed US$600billion [2]. In 
England and Wales, dementia is the leading cause of death overall, accounting for 
11.6% of all deaths registered in 2015 [3]. Recent studies suggest the incidence of 
dementia, particularly in men, may be declining in Western countries; it is unclear 
which causes of dementia are declining, and this may be underpinned by better 
management of vascular risk [4,5]. In coming years, the largest increase in dementia 
prevalence is expected in low and middle-income countries, which show patterns of 
increasing cardiovascular disease, hypertension and diabetes [2]. AD is the single 
biggest cause of dementia – accounting for 50-75%, and is primarily a condition of 
later life, roughly doubling in prevalence every five years after age 65 [2]. 
 
Aetiology 
Whilst the vast majority of AD occurs on an apparently sporadic basis, mutations in 
three genes – amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 
2 (PSEN2) – cause a rare (<0.5%) familial form of AD (fAD). Symptoms develop 
earlier than in sporadic AD, typically between 30 and 50 years of age [6]. 
 
“Typical” late onset AD is likely to be driven by a complex interplay between genetic 
and environmental factors. It is now thought that ~70% of AD risk is attributable to 
genetic factors. The APOE gene, which has three variants, 2, 3 and 4, is the 
single biggest risk for sporadic AD: compared to non-4 carriers, 4 heterozygotes 
have an odds ratio (OR) for AD ~3, rising to ~12 in homozygotes [7]. Genome-wide 
association studies (GWAS) using many thousands of samples have identified more 
than 20 genetic risk factors, implicating inflammatory, cholesterol metabolism and 
endosomal-vesicle recycling pathways [8]. In particular, microglial activation in 
response to amyloid deposition is now recognised to play a key role in AD 
pathogenesis. These relatively common risk genes each confers only a very small 
increased risk, but when combined in a polygenic risk score, can almost double case 
prediction from chance [9]. Focussed genetic approaches and studies using next 
generation sequencing have also revealed a number of other low frequency genes 
conferring relatively high risk for AD, which in turn are providing insights into 
pathogenesis (Figure 1).   
 
Epidemiological evidence suggests education and physical exercise may protect 
against AD, whereas mid-life hypertension and diabetes adversely influence risk 
[10]. Obesity has long been considered a risk for dementia and AD, but this has 
recently been questioned [11]. The mechanisms by which vascular risk factors might 
influence AD remain unclear, not least as few epidemiological studies have 
pathological confirmation of diagnosis. Vascular risk factors may increase the risk of 
clinical AD through a ‘double-hit’ with superimposed cerebrovascular damage, or 
vascular damage might influence the development of AD pathology directly. 
 
Pathology 
The cardinal features of Alzheimer pathology are amyloid plaques and neurofibrillary 
tangles (NFTs) (see Figure 2). In addition, neuropil threads, dystrophic neurites, 
associated astrogliosis, and microglial activation are seen, and cerebral amyloid 
angiopathy frequently co-exists [12]. The downstream consequences of these 
pathologic processes include neurodegeneration with synaptic and neuronal loss 
leading to macroscopic atrophy. Mixed pathology frequently occurs particularly in 
older individuals, and includes vascular disease and Lewy bodies [13]. Indeed, even 
in familial AD cases Lewy body pathology often co-exists, the mechanism for which 
remains uncertain [14]. TDP-43 pathology is increasingly recognised as an important 
co-pathology [15].  
 
Amyloid plaques are extracellular accumulations principally composed of abnormally 
folded Aβ with 40 or 42 amino acids (Aβ40 and Aβ42), two by-products of amyloid 
precursor protein (APP) metabolism. Aβ42 is more abundant than Aβ40 within 
plaques due to its higher rate of fibrillisation and insolubility. Amyloid deposition does 
not always follow a stereotyped pattern of progression, but broadly speaking 
develops in the isocortex, and only latterly affects subcortical structures. Unlike 
NFTs, amyloid plaques involve the entorhinal cortex and hippocampal formations to 
a lesser extent [12]. Different staging systems for Aβ including those from Braak and 
Braak [16], Thal criteria [17] and Consortium to Establish a Registry for Alzheimer 
Disease (CERAD) [18]. 
 
NFTs are primarily composed of paired helical filaments (PHF) consisting of 
hyperphosphorylated tau. Tau pathology typically begins in the allocortex of the 
medial temporal lobe (entorhinal cortex and hippocampus) before spreading to the 
associative isocortex. Primary sensory, motor and visual areas tend to be relatively 
spared. Neuronal and synapse loss typically parallel tangle formation, and as such 
the clinical features and severity of AD are better correlated with NFT pathology [12], 
whilst -amyloid pathology reaches a plateau early in the symptomatic phase of the 
disease [19]. 
 
Several criteria have been proposed for the pathological diagnosis of AD. Early 
attempts using either amyloid plaques or NFT were limited by low specificity or 
sensitivity [20]. Previous pathological criteria for AD from the National Institute of 
Aging and Reagan Institute combined the CERAD neuritic plaque score with the 
Braak and Braak NFT staging, deriving three diagnostic categories: high, 
intermediate and low likelihood. An AD diagnosis could only be made if criteria for 
high or intermediate likelihood of AD were met in conjunction with a dementia 
diagnosis [21]. A limitation of this system is that it did not address individuals dying 
with a high burden of AD pathology but without clinical symptoms. Updated NIA-AA 
neuropathological guidelines attempt to address this, acknowledging the potential for 
disconnect between the clinical picture and neuropathological changes [22]. 
 
Pathogenesis 
The amyloid hypothesis, the prevalent theory of AD pathogenesis, suggests that 
accumulation of pathological forms of Aβ, produced by sequential cleavage of the 
amyloid precursor protein (APP) by the - and -secretase enzymes in the brain is 
the primary pathological process, driven through an imbalance between Aβ 
production and Aβ clearance. The formation of NFTs and subsequent neuronal 
dysfunction and neurodegeneration, perhaps mediated via inflammation, are thought 
to be downstream processes [23] (see Figure 3). Strong support for a central role for 
A comes from genetics: all fAD mutations are involved either in Aβ generation or 
processing and result in relative overproduction of toxic forms of -amyloid. 
Conversely, an APP missense mutation (A673T) results in a lifelong decrease in 
APP cleavage by β-secretase conferring a reduced clinical risk of AD [24]. In 
sporadic disease, ApoE is involved in amyloid clearance, as are many other risk 
genes (Figure 1).  
 
Whilst fibrillar amyloid within dense-core plaques was originally thought to be critical 
to the development of AD, it is now thought that soluble Aβ oligomers may be the 
most pathological forms: oligomers purified from AD brains and applied to neurons in 
vitro inhibit long-term potentiation, cause synaptic dysfunction, damage dendritic 
spines and cause neuronal death [25,26]. Human oligomers also induce 
hyperphosphorylation of tau at AD-relevant epitopes and cause neuritic dystrophy in 
cultured neurons [27]. Plaques may therefore act as a ‘reservoir’ from which amyloid 
oligomers diffuse, or may even act as a protective mechanism, sequestering toxic Aβ 
series until they reach a physiologic saturation point [28]. 
 
Whilst accumulation of A is necessary for a diagnosis of AD, the fact that a 
significant proportion of elderly individuals die with evidence for significant -amyloid 
deposition without symptoms shows that it is not sufficient for AD-dementia. The Aβ 
soluble oligomer:plaque ratio may be lower in patients with asymptomatic 
amyloidosis than patients with AD-dementia, supporting the concept that plaques 
may act as a protective reservoir [29]. Tau is clearly a vital part of the process that 
leads to AD, as evidenced by the requirement for both A and tau pathology for a 
diagnosis for AD, and the close association between neurodegeneration and tau 
load. However, whilst mutations in the tau gene lead to accumulation of tau and a 
variety of neurodegenerative dementias within the frontotemporal dementia spectrum 
[30], unlike mutations in -amyloid genes, tau mutations alone do not cause AD. 
 
The advent of cerebrospinal fluid (CSF) and positron-emission tomography (PET) 
biomarkers of A and tau pathology has led to numerous studies exploring the 
progression and interaction between these pathologies in vivo. Such studies in 
healthy elderly individuals and patients with both sporadic [31] and familial AD  [32] 
provide further evidence that amyloid pathology develops many year before clinical 
symptoms, and precede changes in CSF tau and tau PET which in turn are 
proposed to predate MRI changes and finally clinical symptoms [31]. These models 
– which as discussed below have led to new criteria for AD – continue to evolve as 
more data become available; and whilst there are considerable data to suggest that 
-amyloid is upstream of tau pathology in AD, some healthy elderly individuals have 
evidence for tau-pathology without -amyloid which may be part of the normal 
ageing process, or reflect a non-AD neurodegenerative pathway [33].  
 
There is much interest in both the mechanisms by which AD proteins targets certain 
brain regions but not others, and how they spread through the brain. Abnormally 
folded Aβ and tau has been shown to induce conformational change in structurally 
normal peptides, much as occurs in prion disease. These may be transferred trans-
synaptically from one neuron to another [34]. The site of the original pathological 
event might then determine which cortical networks are affected, and, through 
differential network breakdown, explain the phenotypic diversity seen in AD. 
 
Whilst amyloid and tau pathology are clearly critical in the pathogenesis of AD, how 
the two are mechanistically linked is unclear. A number of lines of evidence suggest 
that the innate immune system play a critical role in AD pathogenesis, and may 
provide this link. Activated microglia co-localise with amyloid plaques at post mortem 
[35]. A number of AD-risk genes, including CR1, CD33, and TREM2 are involved in 
immune system pathways, [36,37]. Clinical studies using PET ligands which bind to 
activated microglia provide further in vivo evidence for a role of neuroinflammation in 
AD [38,39]. The question of whether (or when) neuroinflammation is protective, 
detrimental, or perhaps both, may well depend on disease stage and genotypes, and 
remains to be fully elucidated. 
 
Clinical features  
The commonest presentation of AD is of an elderly individual with insidious, 
progressive problems centred on episodic memory. At this stage, the patient may 
fulfil criteria for amnestic mild cognitive impairment (MCI). Topographical difficulties 
subsequently commonly emerge, alongside difficulties with multi-tasking, and loss of 
confidence. As the condition progresses, cognitive difficulties become more profound 
and widespread so as to interfere with activities of daily living; at this stage a patient 
can be diagnosed with AD dementia. Increasing dependence is the rule, and later in 
the disease behavioural change, impaired mobility, hallucinations and seizures may 
emerge. Death is on average 8.5 years from presentation [40].  
 
A number of atypical (non-memory) clinical syndromes are also recognised, 
particularly in younger-onset cases. These include posterior cortical atrophy (PCA), 
logopenic aphasia (LPA) and the frontal variant of AD. In PCA, whilst amyloid is 
widely distributed, the burden of tau pathology and atrophy is at least initially 
focussed on the parieto-occipital lobes, and patients typically present with prominent 
visuospatial and visuoperceptual problems and dyspraxia with relatively preserved 
memory [41]. In LPA, patients present with prominent word finding pauses, anomia 
and impairments in working memory [42]. Frontal AD, which is rare, can closely 
resemble behavioural variant frontotemporal dementia [43]. fAD tends to have a 
typical amnestic presentation, albeit at a much younger age. Some PSEN1 
mutations are associated with additional features including prominent myoclonus, 
seizures and spastic paraparesis [44]. 
 
Diagnostic criteria 
With the recognition that the pathological changes occur years prior to symptoms, 
and the advent of biomarkers of -amyloid and tau pathology and MRI measures of 
atrophy, diagnostic criteria have evolved both to allow for the diagnosis to be made 
earlier and with increased molecular specificity. The most recent diagnostic criteria 
from both the National Institute of Aging (NIAA) and the International Working Group 
(IWG-2) now incorporate one or more preclinical AD phases, where biomarker 
evidence of AD pathology exists in the absence of symptoms [45–47]. Whilst a 
definitive diagnosis of AD still requires pathological confirmation, the NIA-AA criteria 
allow dementia, or mild cognitive impairment, to be attributed to underlying 
Alzheimer pathology with high, intermediate or low likelihood by incorporating 
biomarker information. Both sets of criteria also recognise atypical, non-amnestic 
presentations [46,48] (see Table).  
 
Important differential diagnoses 
In patients presenting to clinic with memory complaints, the differential diagnosis is 
broad. Causes other than AD include individuals anxious about perceived memory 
loss in the absence of objective evidence for impairment, the so-called “worried well”; 
individuals with affective disorders; and the effects of drugs and alcohol. Other 
mimics of AD include other neurodegenerative disorders including Lewy body 
dementia and frontotemporal dementia; vascular cognitive impairment; infectious, 
inflammatory and metabolic conditions; and a range of miscellaneous causes 
including transient epileptiform amnesia and obstructive sleep apnoea.  
 
Diagnostic approach 
The mainstay of the diagnosis of AD remains the clinical assessment, and in 
particular the clinical interview with the patient and an informant, and a cognitive and 
focussed physical examination. Neuropsychology allows for the quantification of both 
the pattern and severity of cognitive deficits against age-related norms. 
 
Blood tests are performed routinely to exclude conditions which may cause, or more 
commonly contribute, to cognitive symptoms, and typically include full blood count, 
renal function, thyroid function, vitamin B12 and folate. Depending on the clinical 
scenario, it may be appropriate to exclude a range of inflammatory, metabolic, and 
infective causes with specific serological tests (e.g anti-nuclear, anti-neuronal, Lgi1 
antibodies, syphilis and HIV serology).   
 
Structural imaging, using computed tomography or ideally magnetic resonance 
imaging (MRI) is recommended for all patients investigated for cognitive impairment 
to exclude structural abnormalities and provide positive diagnostic information [49]. 
The presence of focal symmetrical medial temporal atrophy has predictive value for 
AD [50]. In PCA-AD, there is typically parieto-occipital atrophy with relative sparing of 
the hippocampi, at least early in the disease [41]. MR imaging allows for the other 
neurodegenerative diseases to be excluded, and for the presence and extent of 
cerebrovascular disease (e.g. white matter hyperintensities and lacunar infarcts) 
which can mimic, or very commonly co-occur with, AD to be evaluated. Cerebral 
microbleeds may be evaluated using iron-sensitive sequences: deep microbleeds 
are more likely to be due to hypertension, whilst lobar microbleeds are more likely to 
be caused by cerebral amyloid angiopathy [51] and, in the correct clinical context, to 
have positive predictive value for AD. Figure 4 shows representative MR images. 
18F-fluorodeoxyglucose (FDG) PET hypometabolism in the parieto-temporal 
association areas, posterior cingulate and precuneus is supportive of an AD 
diagnosis [52].  
 
Amyloid PET imaging (Figure 5) is now available clinically, with three agents 
approved by the European Medicines Agency and the US Food and Drug 
Administration. Florbetapir, flutemetamol and florbetaben all bind fibrillary -amyloid, 
and closely correlate with -amyloid burden at post-mortem [53–55]. To date, 
amyloid PET is not routinely reimbursed in most countries; a number of ongoing 
studies are currently evaluating its clinical utility and cost-effectiveness [56]. Tau 
PET imaging, using tracers such as AV1451, is a recent development which is 
currently only used for research purposes [57]. 
 
Cerebrospinal fluid (CSF) examination can be used both to exclude rare, reversible 
causes of cognitive impairment, but also to aid in a positive, molecular diagnosis of 
AD. The typical CSF pattern in AD is low Aβ1-42 and elevated levels of both tau and 
phospho-tau (p-tau); this pattern also has value in predicting which individuals with 
MCI will develop AD [58] and as a result are included in diagnostic criteria [59]. 
There are to date no AD-specific blood based biomarkers in routine clinical use [60].  
 
Genetic testing, with appropriate consents, can be used to identify autosomal 
dominant causes of AD where these are suspected. The increasing availability of 
genetic panels using next generation sequencing allows for large numbers of genes 
to be tested concurrently at reasonable costs. Routine testing of genetic risk factors 
(e.g. ApoE status) is not currently recommended.  
 
Treatment/management 
Disease-modifying treatments, i.e. those proven to alter the underlying disease 
pathology or disease course, are not yet available. Optimal management needs to 
be tailored to the individual patient and their specific circumstances, and to adapt as 
the disease progresses. Both the patient and carers should be involved in decision-
making, with all reasonable steps taken to allow for patient involvement even as 
cognition declines; a multi-disciplinary approach including medical professionals, 
nurses, social services and charities/support services is vital. Important issue to 
consider include driving, noting that a diagnosis of AD does not necessarily preclude 
driving if symptoms are mild and executive and parietal functions are relatively 
preserved; support at home; finances; and future planning especially while the 
individual has capacity to make decisions. Referral to palliative care to discuss end-
of-life planning can be particularly valuable, ideally in advance of end-stage 
dementia. 
 
Acetyl-cholinesterase inhibitors (AChEI) (donepezil, galantamine and rivastigmine) 
are the mainstay of symptomatic treatment, increasing acetylcholine availability by 
inhibiting its breakdown in the synapse. Peripheral cholinergic side effects such as 
leg cramps and gastro-intestinal upset are common but usually well tolerated, 
especially when the drugs are introduced at low dose and titrated slowly. AChEI 
should be avoided or used with caution in individuals with heart conduction defects 
due to the risk of brady-arrhythmias. AChEI have proven beneficial effects in mild to 
severe AD, with most evidence at the mild-to-moderate stage [61]. There are fewer 
data on measures of behavioural disturbance and activities of daily living, but some 
evidence of benefit. In all domains, however the benefit observed in clinical trials is 
modest at best. There is no evidence that one drug in the class is more efficacious 
than another [61]; differences in the frequency of dosing, dose variation, timing of 
escalation, and delivery (oral and transdermal) provide options that can be tailored to 
individual patients. The DOMINO-AD study demonstrated that withdrawal of 
donepezil in moderate-severe AD increased the risk of nursing home placement in 
the following 12 months of treatment, but not in the following three years. The 
authors suggested that withdrawal of treatment may have potential risks, even when 
the benefits of continuing are not clear [62]. 
Memantine is an alternative symptomatic treatment, licenced for moderate-severe 
AD. Memantine, a low affinity NMDA receptor antagonist, aims to reduce L-
glutamate excitatory neurotoxicity without interfering with its physiological actions. 
Side effects include constipation and headache. Memantine has been shown to have 
a small but clinically appreciable benefit on cognition and functional decline in 
patients with moderate-severe AD, with some evidence it reduces the likelihood of 
patients developing agitation [63].  There is now some evidence for combination 
therapy using an AChEI and memantine. A recent meta-analysis found weak 
evidence for improved cognition with dual-therapy, but there was evidence of 
improved behavioural symptoms in moderate-severe AD [64]. 
Concurrent psychiatric disturbances are common and often difficult to treat. 
Depression and anxiety are frequently seen in AD and have significant impact on 
quality of life, caregiver burden and risk of institutionalisation [65]. There is only 
limited evidence of benefit for antidepressant treatment for depression [66]. There is 
some evidence for benefit of psychological treatments in reducing depression and to 
a lesser extent, anxiety in patients with dementia [65]. Tricyclic antidepressants can 
worsen confusion and should be avoided.  
Agitation, aggression and psychosis may develop in later-stage dementia. Atypical 
antipsychotics are usually favoured over typical agents but regardless of drug, 
benefits are moderate [67], and no treatments are licensed for behavioural 
symptoms in dementia. Serious adverse events include chest infection, stroke and 
death. Consequently, antipsychotics should be avoided if possible and limited to 
those with neuropsychiatric symptoms, particularly psychosis, that are severe, 
debilitating or posing safety risks [68]; ongoing use needs regular review. Where 
required, the best evidence is for low dose risperidone [69]. Non-pharmacological 
approaches are preferred and include communication skills training, music therapy 
and person-centred care training which have some evidence of benefit [70]. 
Future prospects  
Although our understanding of AD has increased dramatically over recent years, it 
remains far from complete. Next generation genetic studies have implicated a 
number of pathways important to the pathogenesis of AD: these are currently being 
explored in cellular and animal models and are already leading to the identification of 
novel drug targets. A more nuanced model of the preclinical phase of AD, no longer 
viewing -amyloid, tau and inflammation as steps along a sequential pathway but as 
part of a cellular phase of AD pathogenesis [71] will also lead to a more 
sophisticated approach to treatment and prevention. 
 The failure of a number of major Phase 3 clinical trials using monoclonal antibodies 
targeting cerebral -amyloid has prompted scepticism about the amyloid hypothesis, 
but perhaps more worryingly about prospects for disease modification in AD more 
generally. It is important however to note that many of these studies have been 
complicated by concern over target engagement and patient selection [72]: not only 
did a proportion of individuals recruited for some of these trials not have evidence for 
AD pathology [28], but most studies have targeted patients with later stage AD, by 
which time -amyloid may no longer be the most appropriate target. There are a 
number of ongoing clinical trials which will report over the next few years – with 
encouraging preliminary findings from a trial of Aducanumab, targeting AD at an 
earlier stage, and showing reduction in amyloid burden and delay in disease 
progression at one year in prodromal and mild AD patients [73]; a number of other 
studies in MCI and mild AD patients are ongoing [74]. There is a concerted effort to 
use strategies to either clear amyloid using immunotherapy or prevent the formation 
of pathological forms (either with β-site APP cleaving enzyme BACE or gamma-
secretase inhibitors/modulators) in the preclinical phase. In fAD cohorts, the DIAN-
TU and API-ADAD studies are identifying at-risk individuals with genetic screening 
[75,76]. The Generation study is recruiting ApoE4 individuals; and the A4 study is 
recruiting healthy elderly individuals with asymptomatic amyloidosis [77]. Alternate 
targets include tau pathology are attracting interest, with a number of clinical trials 
ongoing. Targeting neuroinflammation also has potential, although there have been 
no positive trials to-date [35]. 
 
If disease modifying therapies do provide a signal for efficacy in patients with 
established disease, it will be vital both to ensure they are affordable and can be 
rolled out quickly and equitably to all who will benefit, which will be a major challenge 
for existing healthcare systems. For disease prevention, it will be necessary to 
identify accurately which individuals are at risk. The development of new disease-
specific biomarkers using PET, CSF and, in due course blood, has already provided 
important insights into the pathways leading to the development of AD. Application of 
these technologies to ever larger cohorts, particularly when combined with genetic 
data will improve our ability to detect individuals at risk of developing AD. Longer 
term follow-up will allow for the development of risk models and biomarkers that can 
predict not only if an individual is at risk of AD, but when – information vital both for 
clinical trials and eventually for personalised medicine. Combining this information 
with epidemiological approaches will provide a rational evidence base for the extent 
to which AD can and cannot be prevented by interventions in early or mid-life [78]. 
 
Ultimately, we foresee a time when polygenic risk score and other health measures 
proven to be risk factors can be combined to create an individualised risk score 
(much like the Framingham cardiovascular risk calculator). At an appropriate age, 
high risk individuals can then be referred for more invasive tests of AD pathology, 
e.g. amyloid imaging, and other, perhaps blood based biomarkers to predict 
proximity to disease, with bespoke treatments with a range of different agents being 
targeted to that individual’s stage of disease. Whilst this model of personalised 
disease prevention may be some way off, advances on numerous fronts make this 
vision, if not yet a reality, at least in sight. 
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Figure/table legends 
 
Figure 1: An overview of genes which have been implicated in AD to date. The  
internal colour corresponds to their understood function. Where there are two  
internal colours, the gene has been implicated in more than one pathway. Genes circled in 
yellow are also thought to influence APP metabolism; genes circled in red are thought to 
influence tau metabolism. The figure is minimally adapted from [8] with permission from 
Elsevier.  
 
Figure 2: Pathology of Alzheimer’s disease. Aβ immunohistochemistry highlights the plaques 
in the frontal cortex (A) and cerebral amyloid angiopathy (CAA) where Aβ accumulates 
within blood vessels (B, arrows). An Aβ cored plaque is shown at higher magnification in (C) 
showing a central core. In severe CAA Aβ accumulates within capillaries (D). Tau 
immunohistochemistry demonstrates both neurofibrillary tangles (E, arrows; H at higher 
magnification) and neuritic plaques (E, double arrow). Neuroinflammation is a prominent 
feature in Alzheimer’s disease and this is evident by the number of reactive microglia (F; G 
at higher magnification). The bar in A represents 50µm in A and F; 100µm in B; 25µm in C 
and E and 15µm in D, G and H. 
 
Figure 3: An overview of the major pathogenic events leading to AD as proposed by the 
amyloid hypothesis. The curved blue arrow indicates that Aβ oligomers may directly cause 
synaptic and neuritic damage and induce tau hyperphosphorylation, in addition to activating 
damaging inflammatory cascades. Figure reprinted from [28], available at 
http://onlinelibrary.wiley.com/wol1/doi/10.15252/emmm.201606210/full. Copyright under 
the Creative Commons Attribution License https://creativecommons.org/licenses/by/4.0/. 
 
Figure 4: MRI images showing: A. characteristic hippocampal atrophy in a typical AD case 
best visualised in the coronal plane on T1; B. parieto-occipital atrophy in a posterior cortical 
atrophy case, here demonstrated in the sagittal plane on T1; C. microbleeds which are best 
visualised on SWI. The posterior distribution seen on this axial image is characteristic of 
CAA; D. extensive periventricular and subcortical white matter hyperintensities best 
visualised on FLAIR, seen here on a coronal image. 
 
Figure 5: Florbetapir amyloid PET scan in healthy control (left) and AD patient (right). Warm 
colours indicate high amyloid accumulation. For clinical purposes florbetapir scans are read 
on a grey scale. 
 
Table: An overview of the different clinical and research diagnostic criteria for AD, and 
terminology used, from the preclinical through the symptomatic stages. The IWG-2 criteria 
do not specifically differentiate between mild cognitive impairment and dementia, focusing 
on diagnosing the underlying disease process rather than the clinical syndrome. 
